Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Key Highlights
- ➤120,900 options granted to five newly hired non-executive employees
- ➤$21.49 exercise price set for 10-year inducement options
- ➤Options vest 25% after one year, then monthly over 36 months
- ➤Damora targets mutant calreticulin-driven blood disorders with clinical development planned in 2026
BOSTON, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Damora Therapeutics, Inc. (NASDAQ: DMRA) (“Damora”), a biotechnology company working to fundamentally redefine care for patients with blood disorders, today announced that it granted equity awards to five newly-hired, non-executive employees on November 1, 2026. The inducement grants were approved by Damora’s independent Compensation Committee of its Board of Directors and were made as material inducements to such individuals’ acceptance of employment with Damora in accordance with Nasdaq Listing Rule 5635(c)(4).
The inducement grants consist of options to purchase an aggregate of 120,900 Damora ordinary shares with a 10-year term and an exercise price of $21.49 per share. All of the options vest as to 25% on the first anniversary of the employees’ start date and in equal monthly installments for the following 36 months. The inducement grants are subject to the terms and conditions of the 2022 Damora Therapeutics, Inc. Inducement Plan, and the terms and conditions of an option award agreement.
Get started
Create a free account to read the full story.